Company: DMAC
Filing Date: 2025-05-13
Form Type: 10-Q
Source: 0001437749-25-016488
Chunk: 0

Company: DiaMedica Therapeutics Inc.
Filing Date: 2025-05-13
Form: 10-Q
Item: Part I, Item 1
Chunk 0
---
                                5                                    23  
  Accumulated deficit                                                                                                                                                                           ( 147,709                             ( 140,002  
  Total shareholders’ equity                                                                                                                                                                       33,954                                40,718  
  Total liabilities and shareholders’ equity                                                                                                                                $                      38,830      $                         46,345  

See accompanying notes to the condensed consolidated financial statements.

2

DiaMedica Therapeutics Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share amounts)

(Unaudited)

                                                               Three Months Ended March 31,                                            
                                                               2025                                              2024                  
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Operating expenses:                                                                                                                  
  Research and development                                     $                                      5,656      $              3,676  
  General and administrative                                                                          2,488                     2,065  
  o perating loss                                                                                   ( 8,144                   ( 5,741  
  Other income, net                                                                                     443                       597  
  Loss before income tax expense                                                                    ( 7,701                   ( 5,144  
  Income tax expense                                                                                    ( 6                       ( 7  
  Net loss                                                                                          ( 7,707                   ( 5,151  
  Other comprehensive loss                                                                                                             
  Unrealized loss on marketable securities                                                             ( 18                      ( 45  
  Net loss and comprehensive loss                              $                                    ( 7,725      $            ( 5,196  
  Basic and diluted net loss per share                         $                                     ( 0.18      $             ( 0.14  
  Weighted average shares outstanding – basic and diluted                                        42,843,938                37,958,000  

See accompanying notes to the condensed consolidated financial statements.

3

DiaMedica Therapeutics Inc.

Condensed Consolidated Statements of Shareholders’Equity

For the Three Months Ended March 31, 2025 and 2024

(In thousands, except share amounts)

(Unaudited)

                                                                                                           Paid-In                   Accumulated Other                                        
                                                                                                                                                                                              
                                                                                                           Capital                   Comprehensive                                            
                                                                                                                                                                                              
                                                                                                                                     Income (Loss)                                            
  Issuance of common shares upon the vesting and settlement of restricted stock units      3,805                        —                                   —         —                    —  
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────